ImmunoGen, Inc.
ImmunoGen, Inc. (IMGN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
imgn · stock forecast · 22 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 22 Wall Street analysts in the past 3 months
Hold
22 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$22.00
Consensus
$14.79
-52.6% upside
Low
$6.36
Median: $16 · Last Close: $31.23
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$14.79
-52.6% upside
High Target
$22
-29.6%
Low Target
$6.36
-79.6%
Current Price
$31.23
as of today
Based on analyst price targets, the IMGN stock price prediction for the next 12 months ranges from $6.36 to $22. The consensus IMGN price forecast of $14.79 implies -52.6% upside from the current price of $31.23.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $31.89 | ↑ 2.12% |
1-day model range: $31.83–$31.95. Peak: $31.95 (+2.12%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IMGN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-12-04 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2023-12-04 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-12-01 | BMO Capital | Downgrade ↓ | Outperform→Market Perform |
| 2023-12-01 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
| 2023-12-01 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2023-12-01 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-11-30 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-11-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-09-13 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
| 2023-09-12 | JP Morgan | Upgrade ↑ | Neutral→Overweight |
Wall Street analysts have recently issued updated ratings on ImmunoGen, Inc. (IMGN) stock. Of the recent 128 rating actions, 22 were upgrades and 26 were downgrades. 22 analysts currently cover IMGN.
Analyst Recommendation Trends
IMGN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 10 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$75M
↓ 84.9% YoY
Revenue Next Year
$357M
↑ 379.0% YoY
EPS This Year
$-0.74
EPS Next Year
$-0.05
↓ 93.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast IMGN EPS of $-0.74 for the current fiscal year, based on estimates from 7 analysts. The IMGN revenue forecast is $75M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IMGN stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMGN price target is $14.79 (-52.6% upside), with an analyst consensus of Hold.
The IMGN short-term stock prediction for tomorrow is $31.89 (+2.12%).
ImmunoGen, Inc. trades on NASDAQ under the ticker IMGN. The IMGN stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 27% of covering analysts.
Frequently asked questions
IMGN forecast · 8 questionsAccording to 22 Wall Street analysts, the average 12-month IMGN price target is $14.79, with a high forecast of $22.00 and a low of $6.36. The median price target is shown in the chart above when available. This implies -52.6% potential upside from the current price of $31.23.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.